Latest: Watch here for details of new products and services.
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
- Companies
- Company details
Cancer Research Technology
Oncology-focused development and commercialisation companyThe company in detail
Profile
Cancer Research Technology (CRT) is an oncology-focused development and commercialisation company that realises cancer patient benefit from publicly-funded research worldwide.
At CRT we bridge the fundamental gap between cutting edge academic research and industrial development of cancer therapeutics and diagnostics. We achieve this by working closely with prestigious international research institutes and funding bodies to develop, protect and commercialise oncology related discoveries. Core activities of business development and drug discovery are supported by specialist, integrated teams of patent, legal, finance and marketing personnel. Our exclusive focus in oncology provides for an unrivalled depth of knowledge and experience in cancer-specific translational development and commercialisation.
CRT is wholly owned by the charity Cancer Research UK, the largest independent funder of cancer research in the world. All proceeds are shared with inventors and their institutions, whilst profits are returned to Cancer Research UK to support further cancer research. The company is well resourced to achieve its mission, with its headquarters and an established R&D facility in London, and a US subsidiary in Boston.
R&D
To view this information, you must subscribe to Partneringtools.
Partnerships
To view this information, you must subscribe to Partneringtools.
Deals
To view this information, you must subscribe to Partneringtools.
Latest News
To view this information, you must subscribe to Partneringtools.
Press Releases
(28th Aug 2007) CRT Begins Critical Role in New Australian Cancer Research Venture More
(21st Aug 2007) CRT Establishes Crystallography Facility at Birkbeck, University of London More
(17th Jul 2007) CRT and The Beatson Institute Announce Research Collaboration in Tumour Imaging with AstraZeneca More
(11th Jul 2007) Abiogen Licenses RFB4 Antibody from Cancer Research Technology More
(22nd Jun 2007) Cambridge Scientist Wins Innovation Award for Cancer Diagnostic Markers More
(20th Jun 2007) Cancer Research Technology Licenses Novel Toll-like Receptor Agents to Innate Pharma More
(4th Jun 2007) ondon, UK: 4th June 2007 - Cancer Research Technology Limited (CRT), the cancer-focused development and commercialisation company, and The University of Manchester today announce the establishment of an alliance with AstraZeneca. More
(14th May 2007) Cancer Research Technology & Cronos Therapeutics Extend Scope of Agreement More
(7th May 2007) Cancer Research Technology plans to expand Development Laboratories More
(2nd May 2007) Cancer Research Technology Licenses Therapeutic Antibodies to Peptech More
(19th Apr 2007) Antisoma Announces Global Agreement with Novartis for Cancer Drug AS1404 More
(2nd Apr 2007) New CEO to Spearhead Laboratory Expansion at Cancer Research Technology More
(1st Mar 2007) Fox Chase Cancer Center and Cancer Research Technology Inc. Initiate Drug Discovery Collaboration More
(27th Feb 2007) Cancer Research Technology Secure Orphan Drug Designation for Fenretinide on Behalf of Cancer Research UK More
(5th Feb 2007) Cancer Research Technology Grants Waypharm S.A.S Option to Novel Platinum Agents More
(30th Jan 2007) Formation of Australia's First Cooperative Enterprise Dedicated to the Development of New Cancer Therapies More
(11th Jan 2007) Cancer Research Technology Announce Milestone following Initiation of Stimuvax® Phase 3 Trial in Non Small Cell Lung Cancer More
(11th Dec 2006) Cancer Research Technology and The Institute of Cancer Research Receive Milestone Payment Related to Vernalis' Hsp90 Programme More
(20th Nov 2006) Cancer Research Technology and The University of Manchester Announce Clinical Pharmacology Collaboration in Oncology with AstraZeneca More
(6th Nov 2006) Cancer Research Technology to Present Discovery Updates at BioEurope 2006 More
(27th Sep 2006) Cancer Research Technology Grants Geneservice Ltd. Distribution Rights of RNA Interference Library Generated at the Netherlands Cancer Institute More
(7th Sep 2006) Nanoparticle-based PDT Collaboration Focuses on Proof of Concept Studies More
(4th Sep 2006) Cancer Research Technology Announce Colorectal Cancer Research Collaboration with AstraZeneca More
(14th Aug 2006) Leading Research Institutes Develop DamID: a Novel Protein-Genome Interaction Mapping Technology More
(10th Aug 2006) J. Barrie Ward to Strengthen CRT's Board of Directors More
(26th Jul 2006) Cancer Research Technology Announce Collaboration with Hammersmith Hospital to develop High Intensity Focused Ultrasound for the Treatment of Cancer More
(3rd May 2006) Cancer Research UK and Cancer Research Technology Unveil Plans to Revive Shelved Anti-Cancer Drugs More
(19th Apr 2006) Pharminox signs option to in-license novel telomere signalling targeted agents from Cancer Research Technology More
(11th Apr 2006) Cancer Research Technology Establishes US Subsidiary and Announces Recruitment of Managing Director More
(29th Mar 2006) Cancer Research Technology Announces Recruitment of Prof. Lloyd Kelland as Head of Biology More
(27th Mar 2006) Cronos Therapeutics and Cancer Research Technology Announce New Anti-cancer Drug Development Collaboration More
(15th Feb 2006) Stealthyx Therapeutics and Cancer Research Technology Announce Co-development Partnership for Tumour-targeted Therapy More
(7th Feb 2006) The University of Barcelona and Cancer Research Technology Partner for AT514 Drug Development Collaboration More
(19th Jan 2006) Galapagos and Cancer Research Technology Announce New Anti-Cancer Drug Discovery Collaboration More
(28th Nov 2005) Spear Therapeutics Raise $8.5 Million to Fund Cancer Drug Development More
(8th Nov 2005) The Norwegian Radium Hospital Research Foundation and Cancer Research Technology form a strategic alliance More
(26th Sep 2005) CellCentric and Cancer Research Technology initiate co-development partnership More
MerLion Pharmaceuticals Pte Ltd and Cancer Research Technology Announce Drug Discovery Collaboration
(20th Sep 2005) MerLion Pharmaceuticals Pte Ltd and Cancer Research Technology Announce Drug Discovery Collaboration More
(22nd Aug 2005) Minichromosome Maintenance Proteins Developed as Markers of a Series of Cancers at the University of Cambridge in Studies Funded by Cancer Research UK and the Medical Research Council More
(16th Jun 2005) Alnylam and CRT Report Grant of Fundamental RNAi Patent by the European Patent Office More
(10th May 2005) Dr Phil L'Huillier appointed as Director of Business Management at Cancer Research Technology More
(9th May 2005) Viragen Licenses 'Anti-CD55 Antibody' Cancer Therapy from Cancer Research Technology More
(26th Apr 2005) Ikonisys Inc. Enters into a Research Collaboration and Option Agreement with Cancer Research Technology Covering Automated Microscopy and Rare Cell Diagnostics in Cancer More
(23rd Mar 2005) Cancer Research Technology Ltd. (CRT) and Genvax, the MMI biobaby focused on cancer vaccines, announced today that they have concluded an exclusive worldwide licence for the commercialisation rights to a novel DNA vaccine portfolio More
(16th Feb 2005) The University of Cambridge, Cancer Research Technology, Cancer Research UK and Perlegen Sciences Collaborate to Analyse Thousands of DNA Samples from Breast Cancer Patients More
(1st Dec 2004) Cancer Research Technology grants AstraZeneca an exclusive license to a key patent in the field of nuclear receptors More
(2nd Nov 2004) Marie Curie Cancer Care and Cancer Research Technology extend relationship for cancer patient benefit More
(29th Sep 2004) Cancer Research Technology and The Institute of Cancer Research complete licence with Vernalis More
(11th Aug 2004) Availability of free licences of European patents on the hereditary breast cancer gene BRCA2 to publicly funded research laboratories and not-for-profit research laboratories. More
(20th Jul 2004) Cancer Research Technology grants exclusive license to Genentech to patent portfolio of an oncology target More
Senior management
To view this information, you must subscribe to Partneringtools.
Board of directors
To view this information, you must subscribe to Partneringtools.
Head office
Cancer Research Technology
Sardinia House,
Sardinia Street
London
WC2A 3NL
United Kingdom
Tel: +44 (0)207 269 3640
Fax: +44 (0)207 269 3641
www
Sardinia House,
Sardinia Street
London
WC2A 3NL
United Kingdom
Tel: +44 (0)207 269 3640
Fax: +44 (0)207 269 3641
www
Contact details
Dr Phil L'Huillier
Director of Business Management
Director of Business Management
Company figures
Formed: 2002
Number of employees: 95
Number of employees: 95
Regional and subsidiary offices
Cancer Research Technology Inc.
One Kendall Square
Bldg 200, 1st Floor
Cambridge
Massachusetts
02139
Massachusetts
Tel: +1 617 225 0574
Fax: +1 617 577 1316
www | email
One Kendall Square
Bldg 200, 1st Floor
Cambridge
Massachusetts
02139
Massachusetts
Tel: +1 617 225 0574
Fax: +1 617 577 1316
www | email
Related categories
- Industry sector
- Biotech
- Diagnostic
- Drug delivery
- Pharmaceutical
- Biotechnology / Assay systems
- Biotechnology / Diagnostic test systems
- Biotechnology / Gene therapy
- Biotechnology / Human therapeutics
- Biotechnology / Human diagnostics
- Biotechnology / Research supplies
- Drug discovery
- Drug discovery / Genomics
- Organizations
- Technology transfer
- Universities
- Pharmaceutical / Prescription
- Research tools / Antibodies
- Research tools / Antigens
- Research tools / Cell lines
- Research tools / Mouse models
- Research tools / Reagents
- Marketing
- Therapeutic target
- Oncology
- Oncology / Bladder cancer
- Oncology / Bone cancer
- Oncology / Brain cancer
- Oncology / Breast cancer
- Oncology / Cervical cancer
- Oncology / Colorectal cancer
- Oncology / Colorectal cancer
- Oncology / Colorectal cancer
- Oncology / Liver cancer
- Oncology / Lung cancer
- Oncology / Lymphoma
- Oncology / Ovarian cancer
- Oncology / Prostate cancer
- Oncology / Skin cancer
- Oncology / Testicular cancer
- Oncology / Tumor (other)
- Oncology / Cancer (other)
- Oncology / Anti-oxidant
- Oncology / Skin cancer / Basal cell carcinoma
- Oncology / Prostate cancer / Benign prostatic hypertrophy
- Oncology / Cancer side effects / Chemotherapy side effects
- Oncology / Cancer side effects / Edema
- Oncology / Womb cancer / Endometrial cancer
- Oncology / Lung cancer / Malignant mesothelioma
- Oncology / Skin cancer / Melanoma
- Oncology / Womb cancer / Uterine cancer
- Oncology / Treatments / Vaccines
- Oncology / Treatments / Chemotherapy
- Oncology / Treatments / Radiotherapy
- Oncology / Leukemia / Acute myeloid leukemia
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us